Stock Analysis

Island said that scheduled surgical preparations for 22 non-human primates allocated to the study have commenced at the United States Army Medical Research Institute of Infectious Diseases at Fort Detrick, Maryland. The company described the step as a significant operational milestone, following the completion …

The company reported statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers. Greater effects were seen at higher IMP761 exposure.

Syntara said on 10 November 2026 that it had halted new enrolment in the Phase 1b trial of SNT-9465, a topical panlysyl oxidase inhibitor. The decision followed an internal review of local tolerability findings from the blinded study population.

Starpharma completed manufacture of the non-radiolabelled clinical material for its lead radiopharmaceutical, DEP HER2-Lu, and submitted a Clinical Trial Application in Europe. The company is preparing for a first-in-human Phase 1 study.

During the quarter the company progressed its US regulatory pathway after the FDA granted its request for a pre-IND Type B meeting on the proposed development program for VB0004 in idiopathic pulmonary fibrosis.

The company said it has commenced its planned field program at the Mount Jackson Gold-Silver Project, which sits within the Walker Lane, a mineralised belt with a long history of gold and silver production. Civil works have started to prepare drill pads and access …

The company reported high-grade copper-gold mineralisation at Turpentine, with drilling extending the interpreted system northwards beyond the existing resource model. The northernmost hole, 26TUR009, returned 14m at 1.57% CuEq from 251m, including 5m at 3.75% CuEq.